文献速递造血干细胞移植与细胞治疗白血病

肿瘤对CAR T细胞的内在耐药是一种可被低剂量辐射利用的动态转录状态

Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation.
PubMed 文献 · Blood Adv · 2023-01-01

该研究探讨肿瘤对CAR T细胞的内在耐药性是否可通过低剂量全肿瘤照射(TTI)改变。在小鼠中发现,低剂量TTI可暂时提高反映肿瘤内在敏感性的转录「死亡受体评分」,其变化时机与有限数量CAR T细胞改善白血病控制相关,提示肿瘤质量与肿瘤负荷同等或更重要。

要点

  • 肿瘤负荷高预示CAR T细胞治疗预后差,但肿瘤内在耐药(肿瘤质量)也是重要预测因素。
  • 低剂量全肿瘤照射可暂时提高肿瘤的转录「死亡受体评分」,反映内在敏感性增加。
  • 该转录变化时机与有限数量CAR T细胞改善小鼠白血病控制相关。

核心结论

  • 肿瘤对CAR T细胞的内在耐药是动态转录状态,低剂量全肿瘤照射可暂时提高死亡受体评分并可能改善疗效。

研究设计与样本

  • 小鼠实验研究,比较低剂量全肿瘤照射与高剂量局部辐射对CAR T细胞疗效的影响。

主要发现

  • 高剂量辐射缩小大块病灶对小鼠总生存的影响小于低剂量全肿瘤照射所有病灶。
  • 低剂量全肿瘤照射可暂时提高肿瘤的转录死亡受体评分。
  • 该转录变化时机与有限数量CAR T细胞改善小鼠体内白血病控制相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement for hematologic malignancies, with some patients achieving long-term remission. However, the majority of treated patients still die of their disease. A consistent predictor of response is tumor quantity, wherein a higher disease burden before CAR T-cell therapy portends a worse prognosis. Focal radiation to bulky sites of the disease can decrease tumor quantity before CAR T-cell therapy, but whether this strategy improves survival is unknown. We find that substantially reducing systemic tumor quantity using high-dose radiation to areas of bulky disease, which is commonly done clinically, is less impactful on overall survival in mice achieved by CAR T cells than targeting all sites of disease with low-dose total tumor irradiation (TTI) before CAR T-cell therapy. This finding highlights another predictor of response, tumor quality, the intrinsic resistance of an individual patient's tumor cells to CAR T-cell killing. Little is known about whether or how an individual tumor's intrinsic resistance may change under different circumstances. We find a transcriptional "death receptor score" that reflects a tumor's intrinsic sensitivity to CAR T cells can be temporarily increased by low-dose TTI, and the timing of this transcriptional change correlates with improved in vivo leukemia control by an otherwise limited number of CAR T cells. This suggests an actionable method for potentially improving outcomes in patients predicted to respond poorly to this promising therapy and highlights that intrinsic tumor attributes may be equally or more important predictors of CAR T-cell response as tumor burden.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kim AB, Chou SY, Kang S, et al. Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation. Blood Adv. 2023. PMID: 37093643. doi:10.1182/bloodadvances.2022009543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。